Objective: Attention-deficit/hyperactivity disorder (ADHD) affects 10%-30% of individuals with epilepsy, yet concerns remain regarding the safety of ADHD medication in this group. The objective of this study was to examine the risk of acute seizures associated with ADHD medication in individuals with epilepsy. AEDs, and across sex, age, and comorbid neurodevelopmental disorders. Significance: We found no evidence for an overall increased rate of acute seizures associated with ADHD medication treatment among individuals with epilepsy. These results suggest that epilepsy should not automatically preclude patients from receiving ADHD medications.
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| INTRODUCTION
Patients with epilepsy have a three-to five-fold increased risk of attention-deficit/hyperactivity disorder (ADHD) diagnosis, [1] [2] [3] and 20%-50% of children with epilepsy exhibit subclinical ADHD symptoms. 4 Untreated, ADHD is associated with severe adverse outcomes, [5] [6] [7] [8] making effective treatment crucial. Yet there are concerns regarding the safety of ADHD medication use in individuals with epilepsy; North American and European regulatory agencies caution that stimulants may lower the convulsive threshold and should be discontinued if seizure frequency increases. 9 However, the empirical evidence for an increased risk of seizures related to ADHD medication is varied and debated, with some studies reporting small risk increases and others reporting null effects or even potential protective effects of ADHD treatment on seizure frequency. 4 At least 2 small open-label clinical trials, one observational study, and 2 double-blind clinical trials have examined the risk of seizures in relation to stimulant ADHD medications, with little evidence for an increased risk in individuals with well-controlled epilepsy. [10] [11] [12] [13] [14] In addition, one open-label trial reported that methylphenidates, one of the most commonly used ADHD stimulant medications, were safe for patients with difficult-to-treat epilepsies. 15 Furthermore, one retrospective study reported a decreased seizure frequency associated with methylphenidate treatment in patients with brain injury and active seizures. 16 Other studies have reported inconclusive results due to limited sample size or potential evidence of seizure exacerbation in patients with active epilepsy. [17] [18] [19] One clinical and 3 observational studies have investigated the association between atomoxetine, a nonstimulant ADHD medication, and seizures, with no evidence of seizure exacerbation. [20] [21] [22] [23] However, many of the previous studies were conducted in small clinical samples, [12] [13] [14] [15] [18] [19] [20] focused on seizure-free populations, 17, 22 and/or were not fully able to control for confounding factors that can vary between individuals (eg, shared liability toward ADHD and epilepsy, disorder severity) and may lead to spurious associations between ADHD medication and seizures. Some of these concerns were addressed in a recent large US health care claims study, using a within-individual design to compare the risk of seizures during ADHD medication and nonmedication periods for the same person. Results suggested that ADHD medication periods were associated with a reduced risk of seizure in patients with and without seizure history. 24 Although well powered, the study was not without limitations; commercial health care claims databases are not population representative, information on treatment and seizure history was limited, and comorbid neurodevelopment disorders (NDDs) were not considered. Polypharmacy may be of particular concern in individuals with NDD multimorbidity, stressing the need to evaluate ADHD medication safety in this patient group. The observed negative association between ADHD medication and seizures also warrants further investigation. Patients with a seizure history may be more likely to be prescribed ADHD medication during periods of low seizure risk, thus possibly inducing a false protective effect. In addition, several recent studies have reported the risk of adverse events, including seizures, to be elevated immediately before medication initiation, which could influence the estimated relative risk associated with starting medication treatment. 25, 26 It is therefore important to further investigate the safety of ADHD medication in samples with more detailed information on seizure history and concurrent antiepileptic drug (AED) treatment, comorbid NDDs, and timing of ADHD medication initiation. To address this, we used nationwide Swedish register data and within-individual comparisons to assess the risk of acute seizures associated with both ADHD medication initiation and repeated ADHD medication periods among individuals with epilepsy, with and without comorbid NDDs. Figure S1 shows a flow diagram of the study population selection. 
Key Points

| Exposure
| Outcome
Outcome event was acute seizures, defined as a seizure sufficiently severe to lead to an unplanned inpatient or outpatient visit to hospital or specialist care with a primary discharge diagnosis for seizures according to ICD-10 codes in the NPR. This operationalization was selected to capture seizures that required acute treatment, rather than ongoing medical management (ie, planned visits).
| Covariates
We included concurrent AED treatment periods as a timevarying covariate, identified by dispensation of drugs in ATC class N03A. AED treatment periods were defined in the same manner as repeated ADHD medication periods (see above). We also identified life-time discharge diagnosis for NDDs in the NPR, including ADHD (ICD-9 314, ICD-10 F90), pervasive and specific developmental disorders including autism (ICD-9 299, 315; ICD-10 F80-F89), intellectual disability (ICD-9 317-319; ICD-10 F70-F79), and tic disorders (ICD-9 307; ICD-10 F95). Finally, we included age at the start of each observation period (5-9, 10-14, 15-18, and 19-26 years) as a categorical time-varying covariate.
| Statistical analyses
| ADHD medication initiation
We compared the incidence rate of seizures during the 24 weeks before and after ADHD medication initiation, with the average incidence rate during the same 48 weeks in the previous year. 26, 36 Follow-up time was split into 0-12 and 13-24 weeks before and after medication initiation. Incidence rate ratios (IRRs) were estimated using conditional Poisson regression, with each individual as a separate stratum. In this way, analyses are adjusted for confounders that are constant in an individual during follow-up including, but not limited to, sex, age at medication initiation, genetic liability for seizures and ADHD, disorder severity, and early life risk factors. We included AED treatment as a time-varying covariate; AED treatment status (0/1) was constant within the individual during each comparison period (ie, baseline, and 24 weeks before and after ADHD medication initiation) but could vary between the periods. Because there were no deaths during the 24 weeks following ADHD medication initiation, all individuals had complete follow-up.
| Repeated ADHD medication analyses
To estimate the association between ADHD medication and seizures in the full study population including information on all ADHD medication dispensations, we first conducted population-level analyses using Cox proportional hazards regression to compare the rate of seizures during ADHD medication periods, to the rate during nonmedication periods. We defined the underlying time scale as time since last seizure and used cluster-robust standard errors to account for correlated data from the same individual. Next, we performed within-individual analyses using stratified Cox regression. Each individual was entered as a separate stratum, and the seizure rate during ADHD medication periods was compared to the rate during the nonmedication periods within the same individuals. In this model, the within-individual hazard ratio (HR) is adjusted for confounding by all unmeasured covariates that are constant within the individual during the follow-up. A detailed description of the statistical method is provided elsewhere. 35 We first estimated the population and within-individual level association adjusted for sex and age as a time-varying covariate (Model 1). Concurrent AED treatment may confound the association between ADHD medication and seizures and serve as an index for unmeasured confounders such as increased engagement with health services. We therefore included AED treatment periods as a time-varying covariate (Model 2), so that AED treatment status (0/1) was constant within each time period but could vary within the individual across the followup. In addition, we ran analyses stratified by concurrent AED treatment to estimate the risk of seizures associated with ADHD medication during periods with and without concurrent AED treatment (Model 3). We stratified analyses by sex (Model 4). Finally, we ran the analyses among individuals with a diagnosis of ADHD in the NPR (Model 5). In this subgroup, we further stratified analyses by the presence or absence of any additional NDD diagnoses (ie, pervasive and specific developmental disorders including autism, intellectual disability, and tic disorders) (Model 6).
| Sensitivity analyses
We conducted several sensitivity analyses to examine the robustness of results from the repeated ADHD medication analyses. In line with previous research, 5 ,34,35 we tested alternative exposure time and outcome definitions to examine the potential influence of misclassification. First, ADHD medication periods were defined as 2 consecutive prescriptions within 90 days, rather than 183 days. Second, 90 days was added to the date of last prescription in each medication period. In these analyses, patients with only one ADHD medication dispensation were assumed to be on treatment during the 90 days following the dispensation. The 90-day cutoff for sensitivity analyses was chosen because 3 months is the maximum quantity of drugs allowed at a single dispensation according to Swedish reimbursement regulations. 31 Third,
we used a stricter outcome definition, including only primary seizure discharge diagnosis linked to unplanned emergency care visits, ambulance rides, or inpatient care requiring overnight stay. Discharge diagnoses for status epilepticus (G41), which by definition is an acute seizure, were also included. Fourth, as concerns regarding seizure risk pertain predominantly to stimulant ADHD medication formulations, and because stimulants and nonstimulants have different mechanisms of action, we also reestimated models in stimulant-only users. There was not sufficient power to estimate the same models in atomoxetine-only users. Finally, we reran the main analyses in the epilepsy subcohort born between 1995 and 2003, and in individuals with continuous AED treatment throughout follow-up. Data management was done in SAS version 9.4 (SAS Institute, Inc.), and analyses were conducted using the R package Generalized Nonlinear Models ("GNM") 37 and STATA version 15.0 (StataCorp LLC).
| Ethical approval
The study was approved by the regional ethics review board in Stockholm, Sweden, and all personal information from the registers was anonymized by Statistics Sweden.
By Swedish law, there is no requirement for informed consent in register-based research. 
| RESULTS
| ADHD medication-initiation analyses
| Repeated ADHD medication analyses
In the full study population born between 1987 and 2003, a total of 11 754 seizure events occurred in 21 557 individuals during 136 846 person-years of follow-up. Among the 1855 individuals (9%) who received ADHD medications during follow-up, there was a total of 3556 ADHD medication periods. In individuals with at least one medication period, 1661 (90%) also had at least one nonmedication period. Table 2 shows the baseline characteristics of the study population separately for individuals with and without ADHD medication. Table 3 shows further details on ADHD medication periods, and AED treatment and seizures around the time of ADHD medication.
Estimates from the Cox regression analyses are presented in Table 4 . In Model 1, adjusted for age and sex, there was no difference in the rate of seizures during ADHD medication and nonmedication periods at the population-level (HR 1.00, 95% CI 0.78-1.28). Within-individual estimates showed a statistically significant decreased rate of seizures associated with ADHD medication periods 0.57-0.94). In Model 3, estimates from population-level and within-individual analyses stratified by concurrent AED treatment showed a decreased rate of seizures associated with ADHD medication periods across strata, although estimates were not statistically significant, with confidence intervals including 1. In Model 4, there were no statistically significant differences in estimates stratified by sex at the population level (P = 0.643) or within individual (P = 0.515). The association between seizures and ADHD medication among individuals with a clinical diagnosis of ADHD was similar to that observed in the full study population (Model 5), and there was no statistically significant difference in estimates in the presence or absence of additional NDDs in this subgroup (Model 6: population-level P = 0.087; within-individual P = 0.307).
| Sensitivity analyses
Results from sensitivity analyses conducted in the full study population born between 1987 and 2003, and results from analyses in the subcohorts born between 1995 and 2003 are presented in Table 5 . In line with the main results, estimates consistently suggested a lower rate of seizures associated with ADHD medication periods in the withinindividual analyses although 95% CIs generally included 1, Median days from first AED to first ADHD medication dispensation is reported for patients who received AEDs prior to/at the start of ADHD medication (n = 1077). Median days between start of ADHD medication period and subsequent seizure is reported for acute seizure events that occurred during an ADHD medication period (n periods = 367). AED, antiepileptic drug.
and no significant association in the population-level analyses. This pattern of results did not differ by exposure definition, either by using a 90-day cutoff to redefine medication status or by adding 90 days to the end of each medication period and including single dispensation as treatment periods, or when using a stricter outcome definition. Results were also similar when restricting analyses to stimulant only users.
Analyses in the subcohort born between 1995 and 2003 who meet criteria for epilepsy also showed no evidence of an increased risk of acute seizures at the population level (HR 0.88, 95% CI 0.71-1.10), and a statistically significant decreased rate of seizures associated with ADHD medication periods in within-individual analysis (HR 0.62, 95% CI 0.44-0.89). Similar results were found in the subcohort of individuals continually treated with AEDs (population- 
| DISCUSSION
Results from this nationwide register-based study do not support the hypothesis that ADHD medication increases the rate of seizures. Rather, ADHD medication periods were generally associated with a lower risk of acute seizures when comparing seizures rates across medicated and nonmedicated periods within the same person. Similar associations were seen when focusing on youth younger than 19 years of age who met criteria for (lifetime) epilepsy, and in youth with active epilepsy as indicated by continuous AED treatment. Although concerns about pharmaceutical treatment of ADHD in individuals with epilepsy are not limited to childhood, these findings are of importance as ADHD is typically diagnosed in childhood or adolescence, and clinical decisions about initiating ADHD treatment may be especially challenging in children with active epilepsy.
Our results provide converging evidence with a number of previous studies, but not all, 19 using varying research designs [10] [11] [12] [13] [14] [15] 24 and showing limited support for the hypotheses that ADHD medication in prescribed doses is associated with an increased risk of acute seizures. In addition, we were able to expand the previous literature by studying the risk across varying definitions of seizure history and epilepsy, and by including persons with a wide range of NDDs in addition to ADHD, including autism, intellectual disabilities, and tic disorders. We did not find evidence that the association between ADHD medication and the risk of acute seizures differed in epilepsy patients with additional NDDs. This suggests that stimulants may be a treatment option even in the presence of NDD multimorbidity and that future research in this area should not exclude this important patient group. Investigation of the seizure rate around ADHD medication initiation suggested relatively stable seizure rates during the 24 weeks before and after medication initiation. Within-individual analyses indicated no significant differences in the rate of seizures during the 24 weeks before and after medication initiation, as compared to the same period in the year prior. These findings do not seem to suggest that ADHD medications are only prescribed in periods of significantly lower seizure risk, and they do not support a large increased risk of seizures immediately after ADHD medication initiation. However, these results must be interpreted with caution as all CIs included 1 and analyses were based on a small number of informative individuals (165 events among 97 individuals).
Results from the analyses of repeated ADHD medication periods replicate findings from a recent large-scale US study 24 and one small clinical study 15 
| Strengths and limitations
This study has several strengths, including the use of nationally representative data, long follow-up time, consideration of underlying seizure risk as well as active epilepsy indicated by ongoing AED treatment, the inclusion of patients with comorbid NDDs, and the use of within-individual analyses to adjust for time-constant confounders that vary between individuals. There are also important study limitations. First, as this is a register-based study, we do not have access to neurologic assessments, EEG, or other neuroimaging to confirm epilepsy. Nonetheless, 2 previous studies have shown that most individuals with epilepsy in Sweden are included in the NPR 38, 39 and the positive predictive validity of epilepsy diagnosis in the Swedish Inpatient Register (a large part of the NPR) has been estimated at 79%. 39 Furthermore, we did not have sufficient power and discriminative validity to study the association across different epilepsy subtypes, 40 or to distinguish patients with well-controlled seizures from those with poorly controlled seizures. Second, current clinical guidelines caution against the use of ADHD medication among individuals with seizures. It is therefore possible that our results are biased due to the reluctance of medical professionals to prescribe ADHD medication in this population, as only individuals who received medication contributed to the risk estimates for ADHD medication. In this study, which included individuals aged between 10 and 26 years of age at the end of follow-up, 64% of those diagnosed with ADHD had received ADHD medication treatment at some point during follow-up. This is somewhat lower than Swedish prescription levels following ADHD diagnosis among children (75%) but similar to levels among adults (55%-60%), 41 suggesting that this is not likely to entirely explain our findings. Third, the definition of medication periods was based on a sequence of dispensed prescriptions that might inaccurately reflect the actual consumption of medication. However, different medication period definitions did not substantially impact the results, indicating that exposure time misclassification is unlikely to fully account for our findings. Furthermore, we did not include information on dosages because correctly identifying reliable and valid indexes of medication doses from prescription register data is challenging, particularly across different types of stimulants. Fourth, our outcome definition only captures seizure events that are sufficiently severe to warrant a hospital or specialist care visit. Because patients with epilepsy are not likely to seek medical treatment for minor or routine seizures, it is possible that ADHD medication may still exacerbate seizures that do not require acute medical attention. Finally, given that this is an observational study we cannot rule out that other unmeasured time-varying factors could still confound the results.
| CONCLUSION
We found no evidence for an overall increased rate of acute seizures severe enough to lead to a hospital or specialist care visit associated with ADHD-medication periods in individuals with epilepsy. In fact, our findings suggest a possible reduced rate of acute seizures associated with ADHD medication periods. These results were robust in individuals with a seizure history, in youth who meet criteria for a lifetime diagnosis of epilepsy, and among youth with active epilepsy. Despite longstanding concerns regarding the safety of stimulant medication use in individuals with epilepsy, our results add to a growing body of research showing limited evidence for an exacerbated seizure risk associated with ADHD medications. Because ADHD can have a significant adverse impact on academic, social, and cognitive functioning, effective treatment of ADHD is crucial. 19, 42 Our findings suggest that epilepsy should not automatically preclude patients from receiving pharmacologic treatment for ADHD. and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
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